Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2023 > Vol 4, №9 (2023) > Targeted lymphadenectomy for breast cancer. Execution method. Clinical case

Targeted lymphadenectomy for breast cancer. Execution method. Clinical case

Shakhnoza Sh. Abdulloeva , Andrey D. Kaprin , Aziz D. Zikiryakhodzhaev , Sergey P. Prokopenko , Eric K. Saribekyan , Elena A. Rasskazova , Mikhail L. Mazo , Ekaterina A. Zanozina

For citation:


  • Abstract
  • About the Author
  • References

Abstract

There is a steady trend towards de-escalation of surgical intervention in the breast cancer treatment strategy. At first, this topic concerned the de-velopment and implementation of methods of organ-preserving operations on the mammary gland itself. With the advent of the concept and the development of the sentinel lymph node biopsy technique, the problem of performing a gentle lymphadenectomy with the prevalence of the cN0 process was solved. In recent years, the most innovative technique has begun to develop, namely targeted lymphadenectomy, which allows per-
forming economical interventions on the lymph pathways with the prevalence of the cN1→ypN0 process, that is, in the presence of a verified metastatic lymph node with complete clinical resorption of metastasis during neoadjuvant polychemotherapy. The article is devoted to the de-
scription of the technique of performing targeted lymphadenectomy.
Key words: breast cancer, targeted lymphadenectomy, sentinel (signal) lymph node biopsy, neoadjuvant polychemotherapy, lymphadenectomy.

About the Author

Shakhnoza Sh. Abdulloeva 1 , Andrey D. Kaprin 2 , Aziz D. Zikiryakhodzhaev 3 , Sergey P. Prokopenko 4 , Eric K. Saribekyan 1 , Elena A. Rasskazova 1 , Mikhail L. Mazo 5 , Ekaterina A. Zanozina 1

1 Herzen Moscow Research Oncology Institute – branch of the National Medical Research Center of Radiology, Moscow, Russia

2 Herzen Moscow Research Oncology Institute – branch of the National Medical Research Center of Radiology, Moscow, Russia; National Medical Research Center of Radiology, Obninsk, Russia

3 Herzen Moscow Research Oncology Institute – branch of the National Medical Research Center of Radiology, Moscow, Russia; Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

4 Herzen Moscow Research Oncology Institute – branch of the National Medical Research Center of Radiology, Moscow, Russia; Patrice Lumumba Peoples' Friendship University of Russia, Moscow, Russia

5 Herzen Moscow Research Oncology Institute – branch of the National Medical Research Center of Radiology, Moscow, Russia; Patrice Lumumba Peoples' Friendship University of Russia, Moscow, Russia

References

1. Classe JM, Loaec C et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat 2019; 173 (2): 343–52.
2. Boughey JC, Suman VJ et al. Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013; 310 (14): 1455–61.
3. Kuehn T, Bauerfeind I et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 2013; 14 (7): 609–18.
4. Boileau JF, Poirier B, Basik M et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 2015; 33 (3): 258–64.
5. Volkova YuI, Zikiryakhodzhayev AD et al. Biopsy of the sentinel lymph node and targeted axillary lymph node dissection in patients with breast cancer after neoadjuvant chemotherapy. P.A. Herzen Journal of Oncology 2022; 11 (6): 44–8.
6. Natsiopoulos I, Intzes S et al. Axillary Lymph Node Tattooing and Targeted Axillary Dissection in Breast Cancer Patients Who Presented as cN+ Before Neoadjuvant Chemotherapy and Became cN0 After Treatment. Clin Breast Cancer 2019; 19 (3): 208–15.
7. Patel R, MacKerricher W et al. Pretreatment Tattoo Marking of Suspicious Axillary Lymph Nodes: Reliability and Correlation with Sentinel Lymph Node. Ann Surg Oncol 2019; 26 (8):
2452–8.
8. Sun J, Henry DA, Carr MJ et al. Feasibility of Axillary Lymph Node Localization and Excision Using Radar Reflector Localization. Clin Breast Cancer 2021; 21 (3): e189–e193.
9. Lowes S, Bell A et al. Use of Hologic Localizer radiofrequency identification (RFID) tags to localise impalpable breast lesions and axillary nodes: experience of the first 150 cases in a UK breast unit. Clin Radiol 2020; 75 (12): 942–9.
10. Swarnkar PK, Tayeh S et al. The Evolving Role of Marked Lymph Node Biopsy (MLNB) and Targeted Axillary Dissection (TAD) after Neoadjuvant Chemotherapy (NACT) for Node-Positive Breast Cancer: Systematic Review and Pooled Analysis. Cancers (Basel) 2021; 13 (7): 1539.

For citation:Abdulloeva Sh.Sh., Kaprin A.D., Zikiryakhodzhaev A.D., Prokopenko S.P., Saribekyan E.K., Rasskazova E.A., Mazo M.L., Zanozina E.A. Targeted lymphadenectomy for breast cancer. Execution method. Clinical case. Clinical review for general practice. 2023; 2023; 4 (9): 135–140 (In Russ.). DOI: 10.47407/kr2023.4.9.00320


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru